Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Horst G. Zerbe"'
Autor:
Horst G. Zerbe, Mario A. Gonzalez, Nadine Paiement, PK Noonan Associates, Llc Richmond, Va, Usa, Qc H S X Canada Intelgenx Corp. Abrams Saint-Laurent, Patrick K. Noonan
Publikováno v:
International Journal of Clinical Pharmacology & Toxicology. :26-31
In order to provide patients who take 450 mg/day bupropion hydrochloride for the treatment of severe depressive disorder with a safe and convenient alternative to currently existing dose regimens, a high-dose bupropion ER tablet formulation containin
Autor:
Thomas C. Foster, Raymond Garrison, Horst G. Zerbe, Samuel Harder, Ajaz S. Hussain, Scott Barnhardt, Carol Karp, Vivian A. Gray, Scott Gochnour, Keith Chan, Amanda Gotto, S. Berge, Patrick K. Noonan, Juan Mantelle, James Hammar, Sharad Govil, Gordon L. Flynn, Swanson David R, Vinod P. Shah, Mario A. Gonzalez, C. Hoiberg, Gary W. Cleary, Colin Barrett, Glenn A. Van Buskirk, Robert M. Gale, Hector Llanos
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 44:327-331
Autor:
Ajaz S. Hussain, Scott Gochnour, Samuel Harder, Thomas C. Foster, James Hammar, Gordon L. Flynn, Hector Llanos, Robert M. Gale, Keith Chan, Amanda Gotto, Patrick K. Noonan, Swanson David R, Juan Mantelle, Gary W. Cleary, Mario A. Gonzalez, Horst G. Zerbe, Carol Karp, C. Hoiberg, Raymond Garrison, Vinod P. Shah, Colin Barrett, Scott Barnhardt, S. Berge, Vivian A. Gray, Sharad Govil, Glenn A. Van Buskirk
Publikováno v:
Pharmaceutical Research. 14:848-852
Autor:
Horst G. Zerbe, Markus Krumme
Publikováno v:
Modified-Release Drug Delivery Technology ISBN: 9780429222450
Controlled-release tablets are oral dosage forms from which the active drug is released over an extended period of time with the aim of decreasing the dosing frequency and reducing peak plasma concentrations, thereby improving patient compliance. Mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db88fdbfc5d408ccae963f3b50ffe09e
https://doi.org/10.1201/9780203910337-9
https://doi.org/10.1201/9780203910337-9
Publikováno v:
Pharmaceutical Research. :30-36
To achieve a fast onset and a sufficiently long duration of action in the long-term treatment of angina pectoris a composite dosage form was developed, consisting of a fast-release initial dose Di and a slow-release maintenance dose Dm. The product i